ACTRN12609000665235
Completed
Phase 2
A Randomised Phase II Trial of Pre-operative cisplatin, 5 fluorouracil and docetaxel +/- Radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the oesophagus and/or Oesphago-gastric Junction.
AGITG0 sites150 target enrollmentAugust 5, 2009
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Adenocarcinoma of the Oesophagus and/or OG Junction
- Sponsor
- AGITG
- Enrollment
- 150
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Histologically proven invasive adenocarcinoma of the oesophagus or gastroesophageal junction.
- •2\.Tumour thought to be T2 or greater or T1 tumours that are poorly differentiated or thought to be node\-positive.
- •3\.Technically resectable disease, as assessed in consultation with the intended surgeon.
- •4\.Tumour is sufficiently F\-18 fluorodeoxyglucose (FGD) avid on the initial staging PET scan to provide sufficient contrast between tumour and the surrounding normal tissues so that a response to the neoadjuvant therapy may be assessed.
- •5\.Written informed consent of the patient according to local ethics committee guidelines.
- •6\.Medically fit for surgical resection, defined as having adequate cardiopulmonary function and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\.
Exclusion Criteria
- •1\. Evidence of extrathoracic or extragastric spread apart from perigastric or mediastinal nodes, which are resectable. (Supraclavicular nodes renders the patient ineligible) 2\. Tumour is located in the cervical oesophagus requiring pharyngolaryngectomy. 3\. Tumour is predominantly within the stomach ie. most of the tumour is not involving the oesophagus or gastroesophageal junction. 4\. Evidence of tracheo\- or broncho oesophageal fistula. 5\. Adequate haematological function. 6\. Adequate renal function 7\. Adequate liver function 8\. Previous radiation therapy to the chest, previous chemotherapy within the last 5 years. 9\. Previous malignancy for the previous 5 years apart from non metastatic Squamous Cell Carcinoma of the skin, Basal Cell Carcinoma or carcinoma in situ of the cervix. 10\. Pregnant, lactating or inadequate contraception.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A randomised Phase II study of two pre-operative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer.Histologically confirmed operable oesophageal cancerMedDRA version: 14.1Level: LLTClassification code 10056104Term: Squamous cell carcinoma of oesophagusSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10056092Term: Adenocarcinoma of oesophagusSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-000640-10-GBVelindre NHS Trust
Active, not recruiting
Not Applicable
A randomised phase II study of pre-operative or peri-operative docetaxel, oxaliplatin, capecitabine (DOX) regimen in patients with locally advanced resectable gastric cancer - IRST 151.01Patient with potentially resectable adenocarcinoma of the stomachMedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-020189-37-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
Completed
Phase 2
Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancerStage II and IIIA breast cancerJPRN-UMIN000003355ational Cancer Center Hospital220
Recruiting
Not Applicable
Safety and efficacy of preoperative combination therapy of chemotherapy and hyperbaric oxygen therapy for resectable pancreatic cancerResectable pancreatic cancerJPRN-UMIN000049855Division of Surgery National Hospital Organization Higashi-Ohmi General Medical Center27
Active, not recruiting
Phase 1
A trial comparing chemotherapy and bevacizumab or lapatinib with chemotherapy alone for cancer of the stomach, oesophagus or the junction of the stomach and oesophagusPatients with histologically verfied lower oesophageal, Siewert Type I, II or III oesophagogastric junction or gastric adenocarcinoma.Type III or gastric tumours should be stage 1b (T1N1, T2a/bN0), II,III or stage IV (T4 N1orN2 M0). Lower oesophageal, Type I and II tumours should be stage II to stage IVa (T1N1, T2N1, T3N0-1, but not T2N0). T4 tumours are eligible if they involve the crura or invade the mediatinal pleural only.The tumour should be operableMedDRA version: 18.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2006-000811-12-GBMedical Research Council Clinical Trials Unit1,100